课题基金 / 基金详情

Phase I trial of PHP with high-dose IL-2

Phase I trial of PHP with high-dose IL-2
PHP 联合高剂量 IL-2 的 I 期试验
批准号:
7491940
负责人:
WOLFRAM E. SAMLOWSKI
金额:
$4.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-08-17 至 2009-06-30

项目摘要

项目成果

WOLFRAM E. SAMLOWSKI的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 大剂量的IL-2在一小部分转移性肾癌或黑色素瘤患者中产生完全缓解(5-10%)。耐人寻味的是,许多IL-2诱导的完全缓解已被证明是持久的,并获得了长达18年的随访。IL-2的临床应用受到严重副作用的限制,尤其是低血压和“血管渗漏综合征”(VLS)。接受高剂量IL-2治疗的患者需要住院接受密切监测和液体、胶体和升压药物的治疗,以治疗以剂量依赖方式发生的低血压。由于心血管毒性,计划的IL-2剂量的很大一部分(1/3到1/2)通常被省略,这可能会影响疗效。我们的实验室和临床研究表明,IL-2治疗后,一氧化氮(NO)的合成被强烈诱导。NO是低血压和血管渗漏的重要介质。我们最近发现了一种很有前途的新药,PHP,一种吡哆醇基化的血红蛋白聚氧乙烯结合物,似乎对人类是安全的,并且由于其分解NO的能力以及其他潜在的有害氧化自由基,具有预防IL-2引起的低血压和VLS的潜力。这项赠款申请旨在支持在大剂量IL-2治疗的同时进行PHP的I期临床研究,以评估该化合物的安全性并确定有效剂量。在特定的目标1中,我们将评估PHP在转移性肾癌或恶性黑色素瘤患者中的安全性。这项研究将确定该药与大剂量IL-2联合使用的剂量限制性毒性(如果有的话),并确定逆转IL-2诱导的低血压的生物有效剂量。在具体目标2中,我们将确定PHP对IL-2治疗患者血流动力学功能的影响,包括评估血压、全身血管阻力、心脏指数、肺动脉压和毛细血管楔压,以及在每个大剂量IL-2疗程中所需的总加压剂量。在具体目标3中,我们将评估中间生物标记物在使用或不使用PHP的IL-2治疗的患者中激活一氧化氮合成途径的潜在有用性,以开发II期测试的分析方法。应该强调的是,从IL-2毒性机制的评估中获得的知识很可能广泛地与理解其他细胞因子如IL-1、肿瘤坏死因子、血管内皮生长因子和IL-12引起的低血压和血管渗漏的病理生理学有关。
英文摘要
DESCRIPTION (provided by applicant): High-dose IL-2 produces complete remissions in a small percentage (5-10%) of patients with metastatic renal carcinoma or melanoma. It is intriguing that many of the IL-2 induced complete remissions have proven durable, with up to 18-year follow-up. The clinical use of IL-2 is limited by severe side effects, particularly hypotension and "vascular leak syndrome"(VLS). Patients treated with high-dose IL-2 require hospitalization for close monitoring and administration of fluids, colloids and pressor medications to treat low blood pressure that occurs in a dose dependent manner. A substantial fraction (1/3 to 1/2) of planned IL-2 doses is usually omitted due to cardiovascular toxicity, which may compromise effectiveness. Our laboratory and clinical studies have shown that synthesis of nitric oxide (NO) is strongly induced following IL-2 treatment. NO is an important mediator of hypotension and vascular leak. We have recently identified a promising new agent, PHP, a pyridoxalated hemoglobin polyoxyethylene conjugate, that appears to be safe in humans and has the potential to prevent both IL-2 induced hypotension and VLS due to its ability to catabolize NO, as well as other potentially injurious oxidative radicals. This grant application is designed to support a Phase I clinical investigation of PHP in conjunction with high-dose IL-2 treatment to evaluate safety of this compound and to establish an effective dose. In Specific Aim 1 we will assess the safety of PHP in patients with metastatic renal carcinoma or malignant melanoma. This study will establish dose-limiting toxicity (if any) of this agent in combination with high dose IL-2, and define a biologically effective dose for reversal of IL-2 induced hypotension. In Specific Aim 2 we will determine the effect of PHP on hemodynamic function in IL-2 treated patients, including assessment of blood pressure, systemic vascular resistance, cardiac index, pulmonary artery pressure and capillary wedge pressure and the total dose of pressors required during each course of high-dose IL-2. In Specific Aim 3, we will assess the potential usefulness of intermediate biomarkers for activation of the nitric oxide synthesis pathway in patients treated with IL-2 with or without PHP, to develop assays for phase II testing. It should be stressed that knowledge gained from evaluation of mechanisms of IL-2 toxicity is likely to be broadly relevant to understanding the pathophysiology of hypotension and vascular leak induced by other cytokines, such as IL-1, TNF, VEGF and IL-12.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epigenetic Potentiation of Interferon using Decitabine
  • 批准号:
    7494488
  • 项目类别:
  • 资助金额:
    $22.63万
  • 财政年份:
    2007
  • 负责人:
    WOLFRAM E. SAMLOWSKI
  • 依托单位:
Epigenetic Potentiation of Interferon using Decitabine
  • 批准号:
    7329204
  • 项目类别:
  • 资助金额:
    $24.37万
  • 财政年份:
    2007
  • 负责人:
    WOLFRAM E. SAMLOWSKI
  • 依托单位:
Phase I trial of PHP with high-dose IL-2
  • 批准号:
    7140115
  • 项目类别:
  • 资助金额:
    $19.46万
  • 财政年份:
    2005
  • 负责人:
    WOLFRAM E. SAMLOWSKI
  • 依托单位:
Phase I trial of PHP with high-dose IL-2
  • 批准号:
    6980307
  • 项目类别:
  • 资助金额:
    $24.61万
  • 财政年份:
    2005
  • 负责人:
    WOLFRAM E. SAMLOWSKI
  • 依托单位:
海外基金